Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes

American Journal of Transplantation

Volumn 13, Issue 8, 2013, Pages 2179-2185

  Canaud, G ^a,b   Kamar, N ^c,d,e   Anglicheau, D ^a,b   Esposito, L ^c   Rabant, M ^b,d   Noel L H ^a,b   Guilbeau Frugier, C ^c,e   Sberro Soussan, R ^a,b   Del Bello, A ^c   Martinez, F ^a,b   Zuber, J ^a,b   Rostaing, L ^c,d,e   Legendre, C ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CHU RANGUEIL   (France)

^d CHU PURPAN   (France)

^e UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Complement; renal allograft pathology; thrombotic microangiopathy

Indexed keywords

BASILIXIMAB; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5B; CYCLOSPORIN A; ECULIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTICLE; CASE REPORT; CELLULAR DISTRIBUTION; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECURRENT DISEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR ENDOTHELIUM;

COMPLEMENT; RENAL ALLOGRAFT PATHOLOGY; THROMBOTIC MICROANGIOPATHY;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; CHRONIC DISEASE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LYMPHOCYTE DEPLETION; MALE; PLASMAPHERESIS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RECURRENCE; THROMBOTIC MICROANGIOPATHIES; VASCULAR DISEASES;

EID: 84881372189     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12319     Document Type: Article

References (22)

1. Levine JS, Branch DW, Rauch J., The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763.
2. Long BR, Leya F., The role of antiphospholipid syndrome in cardiovascular disease. Hematol/Oncol Clin N Am 2008; 22: 79-94, vi-vii.
3. Alarcon-Segovia D, Cardiel MH, Reyes E., Antiphospholipid arterial vasculopathy. J Rheumatol 1989; 16: 762-767.
4. Lie JT., Vasculopathy in the antiphospholipid syndrome: Thrombosis or vasculitis, or both ? J Rheumatol 1989; 16: 713-715.
5. Hughson MD, McCarty GA, Brumback RA., Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol 1995; 26: 716-724.
6. Nochy D, Daugas E, Droz D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999; 10: 507-518.
7. Daugas E, Nochy D, Huong DL, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 42-52.
8. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM., Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long-term outcome. Arthritis Rheum 2004; 50: 2569-2579.
9. Canaud G, Bienaime F, Noel LH, et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 2010; 10: 2051-2060.
10. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552-559.
11. Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12: 3337-3354.
12. Noris M, Mescia F, Remuzzi G., STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622-633.
13. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-2563.
14. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
15. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011; 11: 2523-2527.
16. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
17. George M, Rainey MA, Naramura M, et al. Renal thrombotic microangiopathy in mice with combined deletion of endocytic recycling regulators EHD3 and EHD4. PLoS ONE 2011; 6: e17838.
18. Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23: 1229-37.
19. Lonze BE, Singer AL, Montgomery RA., Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 362: 1744-1745.
20. Shapira I, Andrade D, Allen SL, Salmon JE., Brief report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012; 64: 2719-2723.
21. Vivarelli M, Pasini A, Emma F., Eculizumab for the treatment of dense-deposit disease. N Engl J Med 2012; 366: 1163-1165.
22. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.